Drug intelligence / Profile preview

sevoflurane + remifentanil + vecuronium

Development stage
Unknown
Lead developer
AbbVie
Modality
Small Molecules
Administration
Inhalation, Intravenous
01

Overview

This drug is a combination of three agents used together primarily during general anesthesia for surgical procedures.\n\n- **Sevoflurane** is a volatile inhalational anesthetic agent used for induction and maintenance of general anesthesia. It acts by modulating ligand-gated ion channels in the central nervous system, enhancing inhibitory neurotransmission via GABA(A) and glycine receptors (agonist action), and inhibiting excitatory neurotransmission via nicotinic acetylcholine, serotonin, and glutamate receptors (antagonist action). It also affects various ion currents including calcium and potassium channels, contributing to muscle relaxation and CNS depression. Sevoflurane has rapid onset and offset due to low blood solubility, making it suitable especially in pediatric anesthesia.\n\n- **Remifentanil** is an ultra-short-acting opioid analgesic that acts as a potent agonist at the mu-opioid receptor producing analgesia during surgery.\n\n- **Vecuronium** is a nondepolarizing neuromuscular blocking agent that competes with acetylcholine at nicotinic cholinergic receptors at the motor end-plate causing skeletal muscle relaxation facilitating intubation and mechanical ventilation during surgery. Its effect can be potentiated by volatile anesthetics like sevoflurane.

02

Targets

NaV (Voltage-gated sodium channels)KATP channel (ATP-sensitive potassium channel)MOR (Mu opioid receptor)Glycine receptorMuscle-type nicotinic acetylcholine receptor

Beyond the preview

Go deeper on sevoflurane + remifentanil + vecuronium.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sevoflurane + remifentanil + vecuronium.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call